Join Sagimet for a virtual investor and analyst day featuring Scott L. Friedman, MD (Icahn School of Medicine at Mount Sinai), who will discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH).

The event will include a discussion on the Company’s lead drug candidate, denifanstat, an oral, once-daily pill and selective FASN and the recent positive Phase 2b FASCINATE-2 data evaluating denifanstat in MASH.

A live question and answer session will follow the formal presentation.